Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024

Rhea-AI Summary

Cerus (Nasdaq: CERS) has announced that it will release its third quarter 2024 financial results on Wednesday, October 30, 2024, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss the financial results and provide a general business overview and outlook.

Interested parties can listen to the live webcast and view presentation slides on the Investor Relations page of Cerus' website at http://ir.cerus.com. Participants are encouraged to register for the call and join 10 minutes before the event starts. A replay of the call will be available on Cerus' website approximately three hours after the call and will remain accessible until November 20, 2024.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus’ website and will be available approximately three hours after the call through Nov. 20, 2024.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241018393377/en/

Jessica Hanover

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When will Cerus (CERS) release its Q3 2024 financial results?

Cerus (CERS) will release its third quarter 2024 financial results on Wednesday, October 30, 2024, after the stock market closes.

What time is the Cerus (CERS) Q3 2024 earnings call scheduled for?

Cerus (CERS) has scheduled its Q3 2024 earnings call for 4:30 P.M. ET on Wednesday, October 30, 2024.

Where can I access the webcast for Cerus 's (CERS) Q3 2024 earnings call?

The webcast for Cerus 's (CERS) Q3 2024 earnings call can be accessed on the Investor Relations page of the company's website at http://ir.cerus.com.

How long will the replay of Cerus 's (CERS) Q3 2024 earnings call be available?

The replay of Cerus 's (CERS) Q3 2024 earnings call will be available on the company's website until November 20, 2024.